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Abstract
Background: There is controversy about the specific pathophysiology of metabolic syndrome (MS) but several
authors have argued that hyperinsulinemia is a key feature of the cluster. We aimed to assess whether the baseline
insulin levels could predict the development of MS in a well characterised cohort of otherwise healthy adults who
were followed over a five year period.
Methods: We identified 2, 350 Koreans subjects who did not have MS in 2003 and who were followed up in 2008.
The subjects were divided into 4 groups according to the baseline quartiles of fasting insulin, and the predictors of
the incidence of MS were analyzed using multivariate regression analysis.
Results: Over the follow up period, 8.5% of the cohort developed MS. However, 16.4% of the subjects in the
highest quartile of the insulin levels developed MS. In a model that included gender, age, the smoking status, the
exercise level, alcohol consumption and the systolic blood pressure, the subjects in the highest quartile of the
insulin levels had more than a 5 times greater risk of developing MS compared that of the subjects in the lowest
quartile. This predictive importance remained significant even after correcting for all the individual features of MS.
Conclusions: These data suggest that high baseline fasting insulin levels are independent determinants for the
future development of MS.
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Background
Metabolic syndrome (MS) has received increased attention
as an important epidemiological tool for predicting cardio-
vascular disease (CVD) and type 2 diabetes (T2DM) [1-8].
MS is a cluster of CVD and T2DM risk factors with a
shared pathophysiology [2,5,9,10]. Although there is still
debate about insulin resistance and hyperinsulinemia
being central to the clustering of these common CVD risk
factors [11,13], they have been recognized as pathophysio-
logic linking factors of MS [14-16]. Early and identification
of those people who are most likely to develop the MS
and/or its component features should lead to targeted and
“tailored” intervention strategies, and particularly lifestyle
modifications such as exercise and dietary changes [17].
So far, there have been only limited data of the relation-
ship between the future development of MS and the base-
line insulin level, which is a surrogate maker of insulin
sensitivity/resistance. Thus, in this large, well character-
ized, cohort study of otherwise healthy subjects without
T2DM or MS, we aimed to assess whether the baseline
insulin levels can predict the development of MS. We
hypothesized that measuring the fasting insulin in healthy
subjects can predict the subsequent development of MS.
Methods
The study population consisted of apparently healthy
Koreans who had a comprehensive health examination
in 2003 and they were re-examined 5 years later (2008)
at Kangbuk Samsung Hospital, College of Medicine,
Sungkyunkwan University. Initially 3, 153 individuals
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excluded. Individuals were excluded if they were on
medication for T2DM (n = 58) or hypertension (n =
142) and/or if they had an elevated fasting plasma glu-
cose level ≥ 126 mg/dL (n = 382). Three hundred forty
two participants were excluded for being diagnosed with
MS at baseline. Individuals were also excluded for
absence of data including fasting insulin level (n = 168).
Thus, 2, 350 participants were eligible and included for
the study (Figure 1).
The study was approved by the institutional review
board at Kangbuk Samsung Hospital. The health exami-
nation consisted of a full medical history and compre-
hensive blood test evaluation. The participants’ height
and weight were measured barefoot and in light cloth-
ing. The body mass index (BMI) was calculated as
weight in kilograms divided by the height in square
meters. Waist circumference was measured with the
subject in the standing position and at the level of
umbilicus by a single examiner. Blood pressure was
measured using a standardized sphygmomanometer
after 5 minutes of rest. Questionnaires were used to
ascertain information regarding the frequency of exer-
cise (none, < 1 time/week, ≥1 time/week), the smoking
status (never, past, current) and the amount of alcohol
consumed (both quantity and frequency). Current smo-
k e rw e r ed e f i n ea st h o s ew h oa d m i t t e dt os m o k i n ga t
the interview. Grams of alcohol consumption were cal-
culated by multiplying the frequency by the amount, as
previously reported [18].
Laboratory examinations were obtained after an over-
night fast. The fasting plasma glucose, total cholesterol
(TC), triglyceride(TG), low-density lipoprotein choles-
terol (LDL-C) and high density lipoprotein cholesterol
Figure 1 Selection of study population.
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Page 2 of 7(HDL-C) concentrations were measured using Bayer
Reagent Packs on an automated chemistry analyzer
(Advia 1650 Autoanalyzer; Bayer Diagnostics, Leverku-
sen, Germany) [18,19]. High sensitivity CRP was mea-
sured by immunonephelometry (Nephelometry, Behring
Nephelometer II, Dade Behring Marburg GmbH, Ger-
many) with a detection limit of 0.2 mg/L (the values <
0.2 mg/L were regarded to be 0.1 mg/L). The fasting
insulin concentration as a surrogate measurement of
insulin sensitivity was measured with an immunoradio-
metric assay (Biosource, Nivelle, Belgium) with intra-
and interassay coefficients of variation of 2.1- 4.5% and
4.7-12.2%, respectively.
Patients were classified as having MS if he or she had
three or more of the following criteria: waist circumfer-
ence ≥ 90 cm in men or ≥ 80 cm in women, elevated
triglycerides ≥150 mg/dl, reduced HDL cholesterol < 40
mg/dl in men and < 50 mg/dl in women, blood pres-
sure: ≥130/85 mmHg or treatment of previously diag-
nosed hypertension, elevated fasting glucose ≥ 100 mg/
dl or treatment of previously diagnosed T2DM [2].
Patient was diagnosed as having diabetes mellitus after 5
years, if she or he was being treated for diabetes or if
the fasting glucose level was higher than or same as 126
mg/dL according to the criteria from American Diabetes
Association [20].
The continuous variables were reported as mean
values with standard deviations and they were compared
using the independent t-test. Categorical variables were
expressed as percentages and they were compared using
c
2-tests. The relationship between the baseline insulin
level and the future development of MS was analysed in
2 steps. First, the subjects were divided into 4 groups
according to the quartiles of the baseline insulin level
(IU/mL): I (≤6.01), II (6.02-7.29), III (7.30-8.97) and IV
(≥8.98). We then used logistic regression analysis to
determine the odds ratio (OR) of developing metabolic
syndrome in the individuals stratified by the quartiles of
the fasting insulin concentration (which was used as a
surrogate measure of insulin resistance). Second, to bet-
ter understand the role of hyperinsulinemia for increas-
ing the risk of MS and this was independent of any MS
component at baseline, we excluded the subjects who
had any MS component at baseline and we reanalysed
the data with logistic regression analysis. We conducted
both unadjusted and adjusted analyses. Adjustments
were made for the following variables: gender, age, the
smoking status, the exercise level (less than once a week
or at least once a week), the amount of alcohol the sub-
ject drank (grams/day) and the metabolic parameters
(systolic blood pressure, HDL-Cholesterol, triglyceride,
fasting glucose, waist circumference). All the significance
tests were 2-tailed, and p values < 0.05 were considered
to be statistically significant. All the statistical analyses
were performed using SPSS version 17.0 software (SPSS
Inc., Chicago, IL, USA).
Results
During the mean follow up of 5 years, 199 of 2350 sub-
jects (8.5%) developed MS. Table 1 summarizes the
baseline characteristics of the study participants accord-
ing to the quartiles of baseline fasting insulin levels.
There were significant differences in the demographics
and risk factors between as the fasting insulin increases
from first quartile to 4
th quartile. As the baseline fasting
insulin level increased, the subjects were more likely to
be obese and on average showed gradually increasing
mean values for fasting glucose, fasting insulin, systolic
blood pressure and lipid profiles.
As seen in Figure 2, the proportion of subjects who
developed MS increased as the quartile of the baseline
fasting insulin level increased from the first to the fourth
quartile in the whole cohort of subjects without any MS
component. For the subjects in the highest quartile for
insulin levels, 16.4% subsequently developed MS in the
whole cohort. The proportion of subjects who developed
diabetes mellitus significantly increased as the baseline
fasting insulin level increased from first to fourth quartile
(Figure 2).
In the whole study cohort, hyperinsulinemia was an
important predictor of future MS (Table 2). When the
odd ratios for the development of MS, according to the
quartile groups of the baseline fasting insulin level, were
analysed with logistic regression analyses, the risk for the
development of MS increased as the quartile of the base-
line fasting insulin level increased from the first to the
fourth quartile after correction for confounding variables.
After adjustment for gender, age, the smoking status, the
exercise level, the amount of alcohol drank and the systolic
blood pressure, the subjects in the highest quartile of the
insulin levels had over a 5 times greater risk of developing
MS as compared to that of the subjects in the lowest quar-
tile (OR: 5.1, 95% CI: 3.1 - 8.2). This predictive importance
remained significant even after adjustment for all the indi-
vidual features of MS, and this underlines the potential
importance of an elevated insulin level for predicting the
development of MS (Table 2).
To better understand the role of hyperinsulinemia for
increasing the MS risk independent of any MS compo-
nent at baseline, we excluded the subjects who had any
MS component at baseline (Table 3). Interestingly, in the
previously healthy subjects who were without any MS
component at baseline, elevated insulin was still a signifi-
cant predictor of a future diagnosis of MS. The subjects
in the highest quartile of the insulin levels had over a 10
times greater risk of developing MS compared to that of
the subjects in the lowest quartile after adjustment for
age, gender, the smoking status, the exercise level and
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Page 3 of 7the amount of alcohol drank (OR: 10.7, 95% CI: 2.4-47.9).
However, Quartile 3 (OR: 2.3, 95% CI: 0.4-12.9) did not
show a significantly increased risk for the development of
MS compared with that of Quartile 2 (OR: 3.0, 95% CI:
0.6-15.2). Thus, there appeared to be a threshold effect in
terms of the development of MS in that the incidence
was only increased in the highest quartile and there was
not a significant difference between quartiles 1, 2 and 3.
For the whole cohort, subjects with high TG showed
the highest incidence amongst 5 components of MS
after 5 years (Table 4). The subjects without any MS
components at baseline, hyperglycemia was the mostly
developed components amongst 5 MS components after
5 years (Table 4).
Discussion
We addressed the hypothesis that measuring the fasting
insulin in healthy subjects would enable predicting the
subsequent development of MS. This study has shown
that in a general cohort of healthy Asian subjects, 8.5%
developed MS over a 5 year period and that elevated
fasting insulin levels predicted the development of sub-
sequent MS even in the subgroup of patients without
any MS component at baseline. This was particularly
seen for the subjects in the highest quartile of the insu-
lin levels when compared to those subjects with lower
fasting insulin levels. Therefore, high baseline fasting
insulin levels independently predicted the development
of MS over time.
Numerous studies have been performed that showed
that insulin resistance is associated with MS per se or
the factors that comprise MS (e.g., NAFLD [21,22],
T2DM [23,24], CVD [25]). In the study by Mykkänen et
al [26]., insulin sensitivity assessed by frequently
sampled intravenous glucose tolerance test and the
minimal model showed significant association with the
number of metabolic disorders. In addition, fasting
hyperinsulinemia has been used as a surrogate estimate
of insulin resistance according to various combinations
of fasting insulin and the glucose concentration such as
Table 1 Baseline characteristics of the participants according to the insulin stratification
I(≤6.01)
(n = 592)
II (6.02-7.29)
(n = 585)
III(7.30-8.97)
(n = 588)
IV(≥8.98)
(n = 585)
p-value
Age(yr)
Male %
41.9 ± 6.3
75.5
42.0 ± 6.4
74.2
40.7 ± 6.2
73.8
40.7 ± 6.0
74.2
< 0.001
0.915
Life style
Alcohol consumption (g/day) 12.6 ± 14.8 12.4 ± 16.9 11.3 ± 15.5 11.8 ± 14.8 0.206
Smoking % (No/Ex/Current) 47.1/18.6/34.3 51.3/20.3/28.4 49.0/23/28.1 42.6/26.8/30.6 0.003
Exercise %
(none/less than once per week/more than once per week)
21.6/31.6/46.8 22.9/33.5/43.6 24.1/39.6/36.2 25/42.7/32.3 < 0.001
BMI(kg/m
2) 22.7 ± 2.4 23.1 ± 2.5 23.8 ± 2.5 24.8 ± 2.8 0.018
Waist circumference (cm) 78.4 ± 8.2 79.1 ± 8.1 80.9 ± 8.1 83.7 ± 8.8 < 0.001
Systolic BP (mmHg) 112.9 ± 12.6 113.4 ± 12.4 114.5 ± 13.8 115.6 ± 13.6 < 0.001
Diastolic BP mmHg) 73.2 ± 9.6 73.4 ± 9.6 73.8 ± 10.1 74.5 ± 10.1 0.022
Fasting glucose (mg/dl) 87.4 ± 8.0 89.0 ± 7.9 90.9 ± 8.1 91.6 ± 7.6 < 0.001
Triglyceride (mg/dl) 112.4 ± 61.2 121.0 ± 64.3 135.2 ± 70.3 154.2 ± 82.6 < 0.001
HDL-cholesterol(mg/dl) 58.7 ± 11.8 58.2 ± 11.6 56.8 ± 11.6 55.3 ± 11.2 < 0.001
LDL-cholesterol(mg/dl) 117.2 ± 30.0 118.6 ± 30.0 119.6 ± 29.4 124.3 ± 31.0 < 0.001
hs-CRP(mg/L) 0.82 ± 1.16 0.78 ± 1.18 0.92 ± 1.46 1.15 ± 1.87 0.04
Values expressed as n (%) or mean ± standard deviation (by Student t -test)
BMI, body mass index; BP, blood pressure; hs-CRP, high-sensitivity C-reactive protein; MS, metabolic syndrome; DM, diabetes mellitus
3.9% 
5.1% 
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Figure 2 Incidence MS and DM (%) according to baseline
fasting insulin quartile in the whole cohort without any MS
component at baseline. Cut off points for the quartiles (IU/mL)
were I: fasting insulin≤6.01, II: 6.02≤ fasting insulin ≤ 7.29, III:
7.30≤fasting insulin≤8.97, IV: fasting insulin≥8.98. MS, Metabolic
syndrome; DM, diabetes mellitus.
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the fasting insulin level per se. Assuming that insulin
resistance and the obesity being the central pathogenic
factor in the development of MS, a recent study
reported the role of leptin, an adipokine associated with
obesity, on the prediction of MS and CVD risk [29].
However, our study is the only study that has measured
the baseline insulin concentration as a surrogate marker
in order to evaluate the risk of developing MS among
individuals with and without any MS component and as
stratified by the fasting insulin concentration.
Morrison et al. have recently shown that an interaction
between the BMI and the HOMA score is associated with
the development of MS in children [30] and De Boer et al.
has shown in children that the features of MS are corre-
lated with the fasting insulin levels [31]. Not surprisingly,
higher fasting glucose within the normal range in children
is associated with increased insulin levels, yet that study
was correlative rather than prognostic [31]. Our study adds
to the growing evidence by showing that elevated insulin
occurs early and it predicts the subsequent development of
MS. We have also found that an elevated fasting insulin
level itself is potentially a key early feature in the pathophy-
siology of the clinical risk factor cluster of MS.
There have been many studies that have shown that
patients with MS are at an increased risk of cardiovascular
atherosclerosis [32-35]. Mehta et al. have recently shown
that measures of insulin resistance, such as HOMA-IR,
add predictive value over and above the diagnosis of MS
itself in terms of the correlation with coronary artery calci-
fication, which is a marker of the atherosclerotic risk [15].
In the study by Tenenbaum et al [36]., insulin resistance
assessed by HOMA-IR was an independent predictor for
new major cardiovascular events among patients with pre-
existing coronary artery disease. Therefore, strategies that
screen patients’ insulin levels and therapies that specifically
target hyperinsulinemia may have value to prevent this
common risk factor for CVD.
There are several limitations in our study. There is
ongoing controversy about whether the concept of
metabolic syndrome is useful to predict CVD and
T2DM [2,5,9]. The diagnosis of MS has recently been
shown to be useful for predicting subsequent CVD
events, including in Asian cohorts [37] and in a recent
meta-analysis [38]. Insulin sensitivity does not account
for 100% of the variation in insulin response [13]. Kim
et al. showed that the fasting insulin concentration
reflects less than 40% of the variability in insulin resis-
tance as measured by a direct technique, although the
fasting insulin concentration is significantly associated
with insulin resistance [28]. This study population was
extremely well characterized, yet it was a homogenous
population and it is representative of an adult Korean
working population. This limits the generalizability of
Table 2 Incidence and odds ratios for the development of MS according to baseline insulin quartile in 5 years of
follow-up in whole cohort
I(≤6.01)
(n = 592)
II (6.02-7.29)
(n = 585)
III(7.30-8.97)
(n = 588)
IV(≥8.98)
(n = 585)
Incident MS %(n) 3.9 (23/592) 5.1% (30/585) 8.5% (50/588) 16.4% (96/585)
Odds ratio (95% CI)
Model 1 1 1.4 (0.8 - 2.4) 2.5 (1.5 - 4.1) * 5.1 (3.1 - 8.2)*
Model 2 1 1.3 (0.7 - 2.4) 2.0 (1.2 - 3.4) † 3.6 (2.2 - 5.8)*
Model 3 1 1.2 (0.7 - 2.1) 1.7 (1.0 - 2.9) 3.0 (1.8 - 5.0)*
Model 4 1 1.1(0.6 - 2.1) 1.5 (0.9 - 2.5) 2.0 (1.2 - 3.3)†
Adjusted factors in the models:
Model 1: Gender, age, smoking status, exercise level, alcohol drinking amount, systolic blood pressure
Model 2: Model 1 + HDL-cholesterol, triglyceride
Model 3: Model 1 + HDL-cholesterol, triglyceride, fasting glucose
Model 4: Model 1 + HDL-cholesterol, triglyceride, fasting glucose, waist circumference
* p < 0.001
† p < 0.05
MS, metabolic syndrome; HDL, high-density lipoprotein; CI, confidence interval
Table 3 Odds ratios for the development of MS
according to baseline insulin quartile in 5 years of
follow-up in subjects without any MS components at
baseline
Quartiles of baseline
fasting insulin level
(IU/mL)
Incident MS Odds ratio (95% CI)
n (%) Unadjusted Adjusted
a
All 28/1171(2.4%)
I(≤5.76) 2/289 (0.7%) 1 1
II(5.77-6.73) 6/294 (2.0%) 3.0(0.6-14.9) 3.0(0.6-15.2)
III(6.74-8.22) 4/292 (1.4%) 2.0(0.4-11.0) 2.3(0.4-12.9)
IV(≥8.23) 16/296 (5.4%) 8.2(1.9-36.0) * 10.7(2.4-47.9) *
Values expressed as n(%) or odds ratio (95% CI)
aAdjusted for age, gender, smoking status(never or past, current), exercise level
(< 1 time/week, ≥1 time/week), alcohol drinking amount(in grams per day)
* p < 0.001
MS, metabolic syndrome; CI, confidence interval
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Although the euglycemic insulin clamp test is currently
the best and most accurate technique for assessing insu-
lin sensitivity, the fasting insulin level was used as the
marker for insulin resistance in this current study [39].
The reason we didn’t use the euglycemic insulin clamp
technique is that it is almost impossible to perform this
test in all the participants in this kind of large study
population. Lastly, we did not analyze the risk for MS
with Cox proportional hazard model or Kaplan-Meir
survival estimate. This study was done in subjects who
performed health examination twice in 5 years of inter-
val, 2003 and 2008. We cannot specify the exact point
when the subjects developed the disease of interest dur-
ing those 5 years. Therefore, Cox proportional hazard
model or Kaplan-Meir survival estimate could not be
used, and this could have lowered the significance of the
results. However, our study result has its own meaning
study in that high baseline insulin concentration pre-
dicts the risk of developing MS among individuals with
and without any MS component and as stratified by the
fasting insulin concentration.
In conclusion, this study is the first to evaluate elevated
fasting insulin as an independent predictive factor for the
development of subsequent MS over a 5 year period in a
well characterized cohort of apparently healthy adults.
This study supports the concept that hyperinsulinemia is
an early feature, if not the central feature, of the cardiovas-
cular clusters of MS. We have to keep in mind the impor-
tance of high fasting insulin levels not just as a surrogate
marker to predict future development of MS, but also the
increased risk for future CVD itself as well. The usefulness
of strategies to reverse hyperinsulinemia, such as lifestyle
modifications, on the prevention of MS and CVD, war-
rants further investigation.
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